ArticleHuman vaccines & immunotherapeutics2021
Seroprevalence of anti-mumps virus IgG antibody titer and voluntary mumps vaccination coverage in young adults in Japan.
Article in Human vaccines & immunotherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
- Mumps vaccination and immune status among Japanese university students: A multicenter cross-sectional study.Journal of public health research · 2024Article
- Mumps serological surveillance following 10 years of a one-dose mumps-containing-vaccine policy in Fujian Province, China.Human vaccines & immunotherapeutics · 2022Article
- Impact of local vaccine subsidization programs on the prevention of mumps in Japan.Human vaccines & immunotherapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Japan, monovalent vaccine against mumps virus (MuV) infection was shifted to a voluntary basis vaccination due to the incidences of aseptic meningitis in the past. According to an analysis of a total of 409 participants aged 18-20 years, overall vaccination coverage rate was 48%. The mean anti-MuV IgG antibody titer of participants with medical history and more than two times vaccination was significantly higher than that in those without a medical history and unvaccinated and single vaccination, respectively. Seropositivity against MuV infection was >50% regardless of the number of vaccinations. Although these results suggest that seropositivity may persist due to asymptomatic infection, it is necessary to implement either a high vaccine coverage or routine vaccination for prevention of periodic mumps epidemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.